NCT04273139 · REGISTRY CONDITION SEARCH

Ibrutinib + Venetoclax in Untreated WM

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: ACTIVE NOT RECRUITING
Registry last update: 2026-05-11

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: * Venetoclax * ibrutinib

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Very Good Partial Response Within 24 Cycles of Therapy

→

outcome · POSTED

Number of Participants With Complete Response (CR) After 6 Cycles

→

outcome · POSTED

Number of Participants With Complete Response (CR) After 12 Cycles

→

outcome · POSTED

Number of Participants With Complete Response (CR) After 24 Cycles

→

outcome · NOT POSTED

Overall Response

→

outcome · POSTED

Rate of VGPR at 30 Months

→

outcome · POSTED

Median Time to Response

→

outcome · POSTED

Median Time to Major Response

→

outcome · POSTED

Progression Free Survival (PFS) at 24 Months

→

outcome · POSTED

Progression Free Survival (PFS) at 36 Months

→

outcome · NOT POSTED

Progression Free Survival (PFS) at 48 Months

→

outcome · NOT POSTED

Time to Next Treatment

→

outcome · POSTED

Number of Participants With Treatment Related Adverse Events as Assessed (CTCAE) Version 5.0

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Participants must meet the following criteria on screening examination to be eligible to participate. Screening evaluations including consent, physical exam, and laboratory assessments will be done within 30 days prior to Cycle 1 Day 1. Bone marrow biopsy \& aspirate, and CT C/A/P will be done within 90 days prior to Cycle 1 Day 1. * Clinicopathological diagnosis of Waldenström macroglobulinemia \[28\]. * Known tumor expression of mutated MYD88 performed by a CLIA certified laboratory. * Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenström macroglobulinemia \[29\]. * Participants with symptomatic hyperviscosity (e.g. nosebleeds, headaches, blurred vision) must undergo plasmapheresis prior to treatment initiation. * Age ≥ 18 years * ECOG performance status ≤2 (see Appendix A) * Measurable disease, defined as presence of serum immunoglobin M (IgM) with a minimum IgM level of \>2 times the upper limit of normal of each institution is required * At the time of screening, participants must have acceptable organ and marrow function as defined below: * Absolute neutrophil count ≥500/uL (no growth factor permitted) * Platelets ≥50,000/uL (no platelet transfusions permitted) * Hemoglobin ≥ 7 g/dL (transfusions permitted) * Total bilirubin \< 1.5 x institutional ULN * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN * Estimated GFR ≥30 mL/min * Females of childbearing potential (FCBP) must use one reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 90 days after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test at screening. * Men must agree to use a latex condom during treatment and for up to 90 days after the last dose of ibrutinib or venetoclax during sexual contact with a FCBP * Ability to understand and the willingness to sign a written informed consent document. * Exclusion Criteria * Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study: * Participants who have one or more prior systemic therapies for WM. * Participants who are receiving any other investigational agents. * Participants with known CNS lymphoma. * Participants with known history of Human Immunodeficiency Virus (HIV), chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring active treatment. Note: Participants with serologic evidence of prior vaccination to HBV (i.e., HBs Ag-, and anti-HBs+ and anti-HBC-) and positive anti-HBc from IVIG may participate. * Concurrent administration of medications or foods that are moderate or strong inhibitors or inducers of CYP3A within 7 days prior to first dose of study drug. * Participants with chronic liver disease and hepatic impairment meeting Child-Pugh class C (Appendix B). * Concurrent administration of warfarin. * Concurrent systemic immunosuppressant therapy within 21 days of the first dose of study drug. * Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug. * Recent infection requiring systemic treatment that was completed ≤ 14 days before the first dose of the study drug. * Known bleeding disorders (e.g., congenital von Willebrand's disease or hemophilia) * History of stroke or intracranial hemorrhage within 6 months prior to enrollment. * Major surgery within 4 weeks of first dose of study drug. * Malabsorption syndrome or other condition that precludes enteral route of administration. * Female participants who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days of last dose of study drug. * Male participants who plan to father a child while enrolled in this study or within 90 days after the last dose of study drug * Participants with known history of alcohol or drug abuse. * Participants with inability to swallow pills. * On any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Participants with a history of non-compliance to medical regimens. * Participants who are unwilling or unable to comply with the protocol.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * Ibrutinib will be administered at a predetermined dose, once daily for 28 days * TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment) * Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2.
intervention Names
Drug: IBRUTINIB
Drug: Venetoclax
label
Ibrutinib and Venetoclax
type
EXPERIMENTAL

interventions

arm Group Labels
Ibrutinib and Venetoclax
description
Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
name
IBRUTINIB
other Names
Imbruvica
type
DRUG
arm Group Labels
Ibrutinib and Venetoclax
description
Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
name
Venetoclax
other Names
Venclexta
type
DRUG

Study design

allocation

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 45
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Proportion of patients with VGPR to therapy within 24 cycles of therapy initiation. (VGPR is \>90% reduction in serum IgM from baseline)
measure
Number of Participants With Very Good Partial Response Within 24 Cycles of Therapy
time Frame
The primary objective of VGPR within 24 cycles of therapy was assessed starting at Cycle 3 Day 1 through the End of Treatment visit, range of 2 to 21 months after the initiation of therapy.

secondary Outcomes

description
Proportion of patients with a complete response after 6 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.
measure
Number of Participants With Complete Response (CR) After 6 Cycles
time Frame
6 Cycles (28 day cycle)
description
Proportion of patients with a complete response after 12 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.
measure
Number of Participants With Complete Response (CR) After 12 Cycles
time Frame
12 Cycles (28 day cycle)
description
Proportion of patients with a complete response after 24 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly.
measure
Number of Participants With Complete Response (CR) After 24 Cycles
time Frame
Complete response to therapy was assessed starting at Cycle 3 Day 1 through the End of Treatment visit, range of 2 to 21 months after the initiation of therapy.
description
Proportion of patients with minor response (MR) , partial response (PR), very good partial response (VGPR), or complete response (CR) to therapy.
measure
Overall Response
time Frame
72 months
description
Proportion of patients with a VGPR at 30 months from beginning therapy.
measure
Rate of VGPR at 30 Months
time Frame
30 Months
description
Time from treatment initiation until achievement of a minor response (reduction in serum IgM \>25%) or better.
measure
Median Time to Response
time Frame
24 months
description
Time from treatment initiation until partial response or better (\>50% reduction in serum IgM)
measure
Median Time to Major Response
time Frame
24 months
description
Time from initiation of therapy until disease progression (\>25% increase in serum IgM and 500 mg/dL absolute increase).
measure
Progression Free Survival (PFS) at 24 Months
time Frame
24 months
description
Time from initiation of therapy until disease progression (\>25% increase in serum IgM and 500 mg/dL absolute increase).
measure
Progression Free Survival (PFS) at 36 Months
time Frame
36 Months
description
Time from initiation of therapy until disease progression (\>25% increase in serum IgM and 500 mg/dL absolute increase).
measure
Progression Free Survival (PFS) at 48 Months
time Frame
48 Months
description
Time from initiation of IVEN protocol therapy until initiation of new line of therapy.
measure
Time to Next Treatment
time Frame
72 months
description
CTCAE version 5.0
measure
Number of Participants With Treatment Related Adverse Events as Assessed (CTCAE) Version 5.0
time Frame
6 Months

Full study description

brief Summary: This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: * Venetoclax * ibrutinib
detailed Description: * This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. * The names of the study drugs involved in this study are: * Venetoclax * ibrutinib * The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * Participants will be on the research study for up to 2 years on combined venetoclax and ibrutinib and 4 years of follow-up . * It is expected that about 50 people will take part in this research study. * The U.S. Food and Drug Administration (FDA) has not approved venetoclax for your specific disease but it has been approved for other uses. \-- Venetoclax is a targeted therapy that blocks BCL-2, a protein that is important for the survival of WM cells. Laboratory studies and early clinical data have shown that the investigational new agent, venetoclax, may kill cancer cells and may cause tumors to shrink. * The U.S. Food and Drug Administration (FDA) has approved ibrutinib as a treatment option for this disease. --Ibrutinib is a targeted therapy that blocks BTK. It has been FDA approved in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), chronic graft vs. host disease (cGVHD), and Waldenstrom's macroglobulinemia (WM). It is also used in research studies in participants with recurrent B-cell lymphoma), diffuse large B-cell lymphoma (DLBCL), and prolymphocytic leukemia. In a study of ibrutinib in relapsed/refractory WM patients, response rates were high and the treatment was well tolerated. * The U.S. Food and Drug Administration (FDA) has not approved the combination of ibrutinib and venetoclax as a treatment for any disease. * The U.S. Food and Drug Administration (FDA) has not approved the MYD88 test. This test is investigational.

Source references

references

citation
Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstrom macroglobulinemia. Blood. 2024 Feb 15;143(7):582-591. doi: 10.1182/blood.2023022420.
pmid
37971194
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2c6b0c93eaf08e5f7ac3
requested nct id
NCT04273139
primary nct id
NCT04273139
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
b034d8fe6b77d20ba0febe26d04524646fe46bf054460549946074e264dd1f09
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2c6b0c93eaf08e5f7ac3
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT04273139
occurrences
context exact
NCT04273139
end
11
exact text
NCT04273139
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/142/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
7121bc0a8e2ba66572497bec1f491bc02609e5293fba549b66a50525a156f719
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice